JP2017513902A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513902A5
JP2017513902A5 JP2016564162A JP2016564162A JP2017513902A5 JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5 JP 2016564162 A JP2016564162 A JP 2016564162A JP 2016564162 A JP2016564162 A JP 2016564162A JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5
Authority
JP
Japan
Prior art keywords
fcrn
afp
pharmaceutical composition
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564162A
Other languages
English (en)
Japanese (ja)
Other versions
JP6792454B2 (ja
JP2017513902A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026860 external-priority patent/WO2015164364A2/en
Publication of JP2017513902A publication Critical patent/JP2017513902A/ja
Publication of JP2017513902A5 publication Critical patent/JP2017513902A5/ja
Application granted granted Critical
Publication of JP6792454B2 publication Critical patent/JP6792454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564162A 2014-04-25 2015-04-21 アルファ−フェトプロテイン(afp)を操作するための方法 Active JP6792454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461984252P 2014-04-25 2014-04-25
US61/984,252 2014-04-25
US201562101539P 2015-01-09 2015-01-09
US62/101,539 2015-01-09
PCT/US2015/026860 WO2015164364A2 (en) 2014-04-25 2015-04-21 Methods to manipulate alpha-fetoprotein (afp)

Publications (3)

Publication Number Publication Date
JP2017513902A JP2017513902A (ja) 2017-06-01
JP2017513902A5 true JP2017513902A5 (enExample) 2018-06-07
JP6792454B2 JP6792454B2 (ja) 2020-11-25

Family

ID=54333408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564162A Active JP6792454B2 (ja) 2014-04-25 2015-04-21 アルファ−フェトプロテイン(afp)を操作するための方法

Country Status (6)

Country Link
US (4) US20170044257A1 (enExample)
EP (2) EP3804745A1 (enExample)
JP (1) JP6792454B2 (enExample)
AU (1) AU2015249946A1 (enExample)
CA (1) CA2983794A1 (enExample)
WO (1) WO2015164364A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520575D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN107576801A (zh) * 2016-03-25 2018-01-12 张少华 一种基于核酸适体荧光探针afp5的甲胎蛋白试剂盒
EP3448429B1 (en) 2016-04-25 2021-01-13 Syntimmune Inc. Humanized affinity matured anti-fcrn antibodies
US20190201496A1 (en) * 2016-09-16 2019-07-04 The Brigham And Women's Hospital, Inc. Blockade of alphafetoprotein (afp) interactions with beta2-microglobulin associated molecules
CN106916222B (zh) * 2017-04-18 2020-05-05 河北渤腾医药技术有限公司 甲胎蛋白检测试剂盒
WO2020037213A1 (en) * 2018-08-17 2020-02-20 Genentech, Inc. In vitro transcytosis assay
CN119013290A (zh) * 2022-04-13 2024-11-22 Ose免疫疗法公司 用于选择性清除抗体的新型分子

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
ES2136664T3 (es) 1992-06-09 1999-12-01 Hoppe Ag Sistema de cierre y conjunto de cerradura.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US20020110556A1 (en) * 1997-08-15 2002-08-15 Moro Ricardo J. Detection and treatment of cancer
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11511847A (ja) * 1995-09-18 1999-10-12 ジェイ. モロ,リカード 癌の検出及び処理
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
EP1879920A2 (en) * 2005-04-29 2008-01-23 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2010138814A2 (en) * 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions

Similar Documents

Publication Publication Date Title
JP2017513902A5 (enExample)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2015534580A5 (enExample)
RU2017115771A (ru) 17a,21-диэфиры кортексолона для применения в лечении опухолей
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
JP2016502504A5 (enExample)
MA33405B1 (fr) Anticorps anti-axl
JP2012046518A5 (enExample)
JP2015500225A5 (enExample)
CL2018001371A1 (es) Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807)
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
NZ630363A (en) Anti-kit antibodies and uses thereof
JP2015534577A5 (enExample)
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
FI4403228T3 (fi) Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
IL214255B (en) Use of antibodies for preparation of medicaments for treatment of cancer associated with a tumor antigen and methods for diagnosis of cancer associated with a tumor antigen
JP2008154589A5 (enExample)
JP2017527582A5 (enExample)
JP2018515137A5 (enExample)
JP2017501848A5 (enExample)
JP2015512412A5 (enExample)